Pfizer Inc. (NYSE:PFE) Shares Sold by Marble Harbor Investment Counsel LLC

Marble Harbor Investment Counsel LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 2.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 342,471 shares of the biopharmaceutical company’s stock after selling 9,439 shares during the quarter. Pfizer comprises approximately 1.1% of Marble Harbor Investment Counsel LLC’s investment portfolio, making the stock its 26th biggest holding. Marble Harbor Investment Counsel LLC’s holdings in Pfizer were worth $9,582,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Olistico Wealth LLC acquired a new stake in Pfizer in the 2nd quarter valued at approximately $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer during the second quarter valued at $29,000. Creekmur Asset Management LLC bought a new stake in shares of Pfizer during the fourth quarter valued at about $32,000. Trivant Custom Portfolio Group LLC lifted its holdings in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the period. Finally, Financial Connections Group Inc. acquired a new stake in Pfizer in the second quarter worth about $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

PFE opened at $29.27 on Monday. The firm has a market capitalization of $165.86 billion, a P/E ratio of -487.83, a PEG ratio of 1.04 and a beta of 0.68. The stock has a fifty day moving average of $29.21 and a 200-day moving average of $28.13. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $34.42.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the prior year, the business earned $0.67 EPS. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. Equities analysts forecast that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.74%. The ex-dividend date was Friday, July 26th. Pfizer’s payout ratio is presently -2,800.00%.

Analysts Set New Price Targets

PFE has been the topic of a number of recent analyst reports. Wells Fargo & Company boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Barclays boosted their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. UBS Group upped their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Finally, Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.